NO20090598L - 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud - Google Patents

6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud

Info

Publication number
NO20090598L
NO20090598L NO20090598A NO20090598A NO20090598L NO 20090598 L NO20090598 L NO 20090598L NO 20090598 A NO20090598 A NO 20090598A NO 20090598 A NO20090598 A NO 20090598A NO 20090598 L NO20090598 L NO 20090598L
Authority
NO
Norway
Prior art keywords
treatment
skin
purine derivatives
disubstituted purine
human skin
Prior art date
Application number
NO20090598A
Other languages
English (en)
Inventor
Miroslav Strnad
Marek Zatloukal
Lucie Szucova
Lukas Spichal
Ludek Frohlich
Karel Dolezal
Frank J Massino
Original Assignee
Inst Of Ex Botany Academy Of S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Ex Botany Academy Of S filed Critical Inst Of Ex Botany Academy Of S
Publication of NO20090598L publication Critical patent/NO20090598L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringe fremgangsmåter og preparater for motvirking av de ugunstige effekter av aldring på pattedyrceller in vitro og in vivo, spesielt humane hudceller og human hud, og behandling av hyperproliferative og relaterte hudsykdommer i pattedyr ved administrering av preparater inneholdende 6,9-disubstituerte purinderivater.
NO20090598A 2006-07-10 2009-02-06 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud NO20090598L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80687106P 2006-07-10 2006-07-10
US11/774,652 US20080009508A1 (en) 2006-07-10 2007-07-09 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
PCT/US2007/073142 WO2008008770A2 (en) 2006-07-10 2007-07-10 6, 9-disubstituted purine derivatives and their use for treating skin

Publications (1)

Publication Number Publication Date
NO20090598L true NO20090598L (no) 2009-04-14

Family

ID=38919793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090598A NO20090598L (no) 2006-07-10 2009-02-06 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud

Country Status (16)

Country Link
US (4) US20080009508A1 (no)
EP (1) EP2043630B1 (no)
JP (1) JP5309023B2 (no)
KR (1) KR101478727B1 (no)
CN (1) CN101646435B (no)
AU (1) AU2007272576B2 (no)
BR (1) BRPI0714161A2 (no)
CA (1) CA2657516C (no)
EA (1) EA015848B1 (no)
ES (1) ES2603216T3 (no)
IL (1) IL196442A (no)
MX (1) MX2009000347A (no)
MY (1) MY158100A (no)
NO (1) NO20090598L (no)
NZ (1) NZ574711A (no)
WO (1) WO2008008770A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960397B2 (en) * 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
NZ597050A (en) 2009-06-29 2014-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
US8680108B2 (en) * 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
EP2395086A1 (en) * 2010-06-09 2011-12-14 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
EP2711423B1 (en) * 2010-06-09 2014-11-05 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
US20130072506A1 (en) 2011-09-16 2013-03-21 Lenka ZAHAJSKA 6,8-disubstituted purine compositions
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CZ306984B6 (cs) 2014-12-15 2017-11-01 Ústav experimentální botaniky AV ČR, v. v. i. 6,8-Disubstituované-9-(heterocyklyl)puriny, přípravky obsahující tyto deriváty a jejich použití v kosmetických a medicínských aplikacích
MD3262046T2 (ro) 2015-02-27 2021-03-31 Incyte Corp Săruri de inhibitori ai PI3K și procedee pentru prepararea lor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
CZ307722B6 (cs) * 2015-08-28 2019-03-27 Univerzita PalackĂ©ho v Olomouci Adeninové deriváty a jejich použití
CZ307868B6 (cs) * 2017-04-28 2019-07-10 Univerzita PalackĂ©ho v Olomouci Deriváty 9-(2-oxacykloalkyl)-9H-purin-2,6-diaminu, přípravky obsahující tyto deriváty a jejich použití
EP4178959A1 (en) 2020-07-13 2023-05-17 Univerzita Palackého v Olomouci Nitrogen heterocyclic cytokinin derivatives, compositions containing these derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371089A (en) * 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
US5021422A (en) * 1989-06-08 1991-06-04 Senetek Plc Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
EP1901817A2 (en) * 2005-07-08 2008-03-26 The Procter and Gamble Company Personal care compositions and methods for the beautification of mammalian skin and hair

Also Published As

Publication number Publication date
US20110224238A1 (en) 2011-09-15
EA200970110A1 (ru) 2009-06-30
AU2007272576B2 (en) 2012-05-17
AU2007272576A1 (en) 2008-01-17
ES2603216T3 (es) 2017-02-24
WO2008008770A3 (en) 2008-04-10
BRPI0714161A2 (pt) 2012-12-25
IL196442A (en) 2015-10-29
MX2009000347A (es) 2009-03-20
WO2008008770A2 (en) 2008-01-17
CN101646435B (zh) 2012-08-22
EP2043630A2 (en) 2009-04-08
MY158100A (en) 2016-08-30
IL196442A0 (en) 2009-11-18
EP2043630A4 (en) 2010-12-29
US20100234401A1 (en) 2010-09-16
US20080009508A1 (en) 2008-01-10
CN101646435A (zh) 2010-02-10
KR20090047457A (ko) 2009-05-12
EP2043630B1 (en) 2016-09-07
EA015848B1 (ru) 2011-12-30
CA2657516C (en) 2016-05-10
NZ574711A (en) 2012-05-25
KR101478727B1 (ko) 2015-01-02
JP2009543799A (ja) 2009-12-10
JP5309023B2 (ja) 2013-10-09
CA2657516A1 (en) 2008-01-17
US20130072505A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
CR10345A (es) Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion
GB2472964A (en) Vectors for delivery of light-sensitive proteins and methods of use
HK1118577A1 (en) Rnai expression constructs rnai
CR11731A (es) Composiciones y procedimientos para su preparación y uso
WO2005062881A3 (en) Gene therapy using transposon-based vectors
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
HRP20050967B8 (hr) Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
TW200732347A (en) VEGF analogs and methods of use
WO2008137758A3 (en) Amino acid lipids and uses thereof
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20064584L (no) Tetrahydropyridoindolderivater
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
UA95105C2 (ru) Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application